HUTCHMED (China) (HCM) Current Deferred Revenue (2015 - 2026)
HUTCHMED (China) (HCM) posted quarterly Current Deferred Revenue of $17.1 million for Q2 2026, down 63.6% year-over-year from $46.8 million in Q2 2025, and up 157.28% quarter-over-quarter from $6.6 million in Q4 2025.
HUTCHMED (China) (HCM) Current Deferred Revenue (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HCM) has reported Current Deferred Revenue for 11 consecutive years, with $17.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Deferred Revenue fell 63.6% year-over-year to $17.1 million; the TTM figure through Jun 2026 stood at $17.1 million (down 63.6% YoY), while the FY2025 annual figure was $31.4 million, up 148.85% from the prior year.
- Current Deferred Revenue grew to $17.1 million in Q2 2026 per HCM's latest filing, from $6.6 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $16.3 billion in Q4 2023 and bottomed at $1.7 million in Q4 2022.
- Historically, Current Deferred Revenue has averaged $2.1 billion across 5 years, with a median of $31.9 million in 2025.
- Annual changes were most pronounced in 2023 — Current Deferred Revenue surged 939994.2% — and 2024, when it slumped 99.92%.
- HUTCHMED (China)'s Current Deferred Revenue stood at $1.7 million in 2022, then soared by 939994.2% to $16.3 billion in 2023, then plunged by 99.92% to $12.7 million in 2024, then sank by 47.69% to $6.6 million in 2025, then jumped by 157.28% to $17.1 million in 2026.
- Business Quant data shows HCM's Current Deferred Revenue at $17.1 million in Q2 2026, $6.6 million in Q4 2025, and $46.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | HUTCHMED (China) | 2.19 Bn | 2.19 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.05 Mn |
| Dec 31, 2025 | 6.63 Mn |
| Jun 30, 2025 | 46.84 Mn |
| Dec 31, 2024 | 12.67 Mn |
| Jun 30, 2024 | 48.15 Mn |
| Dec 31, 2023 | 16.27 Bn |
| Jun 30, 2023 | 52.26 Mn |
| Dec 31, 2022 | 1.73 Mn |
| Dec 31, 2020 | 1.60 Mn |
| Dec 31, 2019 | 2.11 Mn |
| Dec 31, 2018 | 2.54 Mn |
| Jun 30, 2018 | 3.75 Mn |
| Dec 31, 2017 | 1.30 Mn |
| Dec 31, 2016 | 2.04 Mn |
| Jun 30, 2016 | 2.90 Mn |
| Dec 31, 2015 | 3.50 Mn |